FDA
-
-
-
-
-
-
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
-
-
-
-
-
-
-
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
-
-
-
-
-
-
-
Renalytix AI (RNLX) Appoints Catherine Coste to its Board
-
-
-
-
-
-
-
New Published Real-World Evidence Shows KidneyIntelXâ„¢ Utility
-
-
-
-
-
-
-
Renalytix announces a c.$20.3 million private placement
-
-
-
-
-
-
-
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
-
-
-
-
-
-
-
Renalytix to Present at Stifel Healthcare Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

